Navigation Links
InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
Date:5/29/2008

2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Reportlinker.com announces that a new ... Acute Heart Failure Global Clinical Trials ... Acute Heart Failure Global Clinical ... GlobalData,s clinical trial report, "Acute Heart Failure Global ... the Acute Heart Failure clinical trial scenario. This ...
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
(Date:9/2/2014)... 2014 Particle Sciences, the leading CDMO for ... development and manufacturing capabilities with the addition of a ... Particle Sciences, Associate Director Clinical Production, "The company has ... square footage, equipment and staff across the board, all ... has over 6000ft 2 of operating cleanroom and ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
... , NEW YORK , Aug. 2 ... medical membership, announced today that, effective August 1, 2010 ... Indemnity Reference Laboratory Networks.  This expansion ensures broader choices for ... on service, quality and choice, and reduces the need for ...
... FRANKLIN LAKES, N.J. , Aug. 2 BD ... global medical technology company, today announced the completion of the sale of its ... blades product platform to one of RoundTable,s portfolio companies, Aspen Surgical Products, Inc. ... On June ...
Cached Medicine Technology:Empire BlueCross BlueShield Expands Lab Networks -- Creating Broader Choice, Robust Competition and Lower Costs for Consumers 2BD Completes Sales of Ophthalmic Systems Unit and Surgical Blades Product Platform 2
(Date:9/2/2014)... 03, 2014 Recently, Top 10 ... companies and announced that JustHost ( http://www.justhost.com/track/seohosts ) ... webmasters. , “The hosting suppliers we recommend are ... competitors on hosting features, uptime and server speed ... Best SEO Hosting says. “We believe that BlueHost ...
(Date:9/2/2014)... Cloud Medical Doctor Software Corporation (Cloud-MDs) ... Practice Business Operations solutions and Billing Services for the ... solutions for all industries announced today that its CEO ... of the CME in Chicago by PRICE Futures Group ... are very proud of the recognition that our CipherLoc ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Complications are rare among ... a new study indicates. However, the researchers ... with a slightly higher risk for certain complications ... more than 18,000 breast cancer patients who had ... with breast reconstruction and were followed for 30 ...
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... 2014 Operators in the Community ... people annually, arranging care and counsel for those in ... are expected to derive $39.4 billion in revenue, which ... income. Over the five years through 2014-15, the subdivision ... 6.6%, including growth of 4.1% in 2014-15. , As ...
Breaking Medicine News(10 mins):Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Award Winning Artist Describe Why They ... May 29 Susan G. Komen for the Cure(R),s ... African-American,leaders -- each with different backgrounds and personal stories ... around the globe to help,end breast cancer forever. The ...
... 29 Kewaunee Scientific,Corporation (Nasdaq: KEQU ) ... Company,s quarterly cash dividend to eight cents per,outstanding ... in the previous,quarter, payable on June 23, 2008 ... on June 9, 2008., Kewaunee Scientific Corporation ...
... 29 Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) ... Meeting of Stockholders Thursday, June 12, 2008 at ... Pickering Hale & Dorr, 60 State,Street, Boston, MA., ... Alseres Pharmaceuticals, Inc., Alseres Pharmaceuticals, Inc. (ALSE) ...
... to Donate One Dollar to Change Lives, CHICAGO, ... a Bite out of Hunger" during its 70th Annual,Donut ... hundreds of Donut,taggers will hit the streets during a ... World War I when volunteers handed out donuts,to troops ...
... and Purdue universities Thursday announced the creation of ... a medical research initiative that will combine the ... swiftly transform discoveries into better patient care and ... has awarded a five-year Clinical and Translational Science ...
... Cancer Center researchers have identified that a combination of ... leukemia cells previously resistant to conventional forms of therapy. ... of the bone marrow caused by a specific genetic ... of leukemia. Imatinib mesylate, or Gleevec, is a highly ...
Cached Medicine News:Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 2Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 3Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 4Health News:Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting 2Health News:The Salvation Army Takes a Bite Out of Hunger 2Health News:Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: